© Fraunhofer ITEM, Ralf Mohr
Fraunhofer Research consortium iCAIR® makes use of synergies to develop new medications against SARS-CoV-2.
The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 74 institutions of the Fraunhofer-Gesellschaft, Europe's leading organization for applied research. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on airway research, our R&D portfolio includes three thematic areas: drug development, chemical safety, and translational biomedical engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.
With a staff of 357 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.